Nevertheless, peripheral neuropathy should be a consideration when selecting therapy for HER2-positive breast cancer patients at high risk of developing it, or in those patients who already have it as a pre-existing condition prior to starting treatment [168]. This evidence concerns the gene ERBB2 and peripheral neuropathy.